Ongentys (Opicapone) is a selective and reversible catechol-O-methyltransferase (COMT) inhibitor, providing an important adjunctive treatment option for managing "off" episodes in patients with Parkinson's disease (PD).
Indications for Ongentys (Opicapone)
Main Indications
Adjunctive treatment for "off" episodes in Parkinson's disease: Used in combination with levodopa/carbidopa, it is indicated for Parkinson's disease patients experiencing "off" episodes.
By inhibiting the COMT enzyme, opicapone can reduce the metabolism of levodopa and prolong its therapeutic effect, thereby improving motor fluctuations.
Key Limitations
It is only suitable for patients already on a levodopa/carbidopa regimen and cannot be used alone.
It is contraindicated in patients who are concurrently using non-selective monoamine oxidase (MAO) inhibitors or who have catecholamine-secreting tumors such as pheochromocytoma.
Dosage Forms, Strengths, and Properties of Ongentys (Opicapone)
Dosage Strengths
50 mg capsules: Dark blue opaque caps and dark pink opaque bodies. Both the capsule bodies and caps are axially imprinted with "OPC" and "50" in white.
25 mg capsules: Light blue opaque caps and light pink opaque bodies. Imprinted with "OPC" and "25" in blue.
Composition
Active ingredient: Opicapone.
Excipients: Lactose, magnesium stearate, pregelatinized starch, etc. Capsule shells contain FD&C dyes, gelatin, and titanium dioxide.
Property Characteristics
Opicapone exists as a yellow powder or crystalline solid with limited water solubility and is administered via the oral route.
Storage Methods for Ongentys (Opicapone)
Storage Conditions
Temperature requirement: Should be stored in an environment below 30°C (86°F) to avoid exposure to high temperatures.
Packaging instructions: The medication is supplied in bottles with child-resistant caps.
Other Relevant Notes
The medication should be stored in a dry place to protect it from moisture.
Keep the original packaging intact to prevent the capsules from being exposed to light or physical damage.
